Pharmacodynamic modeling of anti-cancer activity of tetraiodothyroacetic acid in a perfused cell culture system

Hung Yun Lin, Cornelia B. Landersdorfer, David London, Ran Meng, Chang Uk Lim, Cassie Lin, Sharon Lin, Heng Yuan Tang, David Brown, Brian van Scoy, Robert Kulawy, Lurdes Queimado, George L. Drusano, Arnold Louie, Faith B. Davis, Shaker A. Mousa, Paul J. Davis

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Unmodified or as a poly[lactide-co-glycolide] nanoparticle, tetraiodothyroacetic acid (tetrac) acts at the integrin αvβ3 receptor on human cancer cells to inhibit tumor cell proliferation and xenograft growth. To study in vitro the pharmacodynamics of tetrac formulations in the absence of and in conjunction with other chemotherapeutic agents, we developed a perfusion bellows cell culture system. Cells were grown on polymer flakes and exposed to various concentrations of tetrac, nano-tetrac, resveratrol, cetuximab, or a combination for up to 18 days. Cells were harvested and counted every one or two days. Both NONMEM VI and the exact Monte Carlo parametric expectation maximization algorithm in S-ADAPT were utilized for mathematical modeling. Unmodified tetrac inhibited the proliferation of cancer cells and did so with differing potency in different cell lines. The developed mechanism-based model included two effects of tetrac on different parts of the cell cycle which could be distinguished. For human breast cancer cells, modeling suggested a higher sensitivity (lower IC50) to the effect on success rate of replication than the effect on rate of growth, whereas the capacity (Imax) was larger for the effect on growth rate. Nanoparticulate tetrac (nano-tetrac), which does not enter into cells, had a higher potency and a larger anti-proliferative effect than unmodified tetrac. Fluorescence-activated cell sorting analysis of harvested cells revealed tetrac and nano-tetrac induced concentration-dependent apoptosis that was correlated with expression of pro-apoptotic proteins, such as p53, p21, PIG3 and BAD for nano-tetrac, while unmodified tetrac showed a different profile. Approximately additive anti-proliferative effects were found for the combinations of tetrac and resveratrol, tetrac and cetuximab (Erbitux), and nano-tetrac and cetuximab. Our in vitro perfusion cancer cell system together with mathematical modeling successfully described the anti-proliferative effects over time of tetrac and nano-tetrac and may be useful for dose-finding and studying the pharmacodynamics of other chemotherapeutic agents or their combinations.

Original languageEnglish
Article numbere1001073
JournalPLoS Computational Biology
Volume7
Issue number2
DOIs
Publication statusPublished - Feb 2011
Externally publishedYes

Fingerprint

Pharmacodynamics
Cell Culture
pharmacology
Cell culture
cancer
Cancer
cell culture
Cell Culture Techniques
neoplasms
Acids
acids
acid
Cell
Modeling
modeling
Neoplasms
Cells
Mathematical Modeling
Resveratrol
tetraiodothyroacetic acid

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Ecology
  • Molecular Biology
  • Genetics
  • Ecology, Evolution, Behavior and Systematics
  • Modelling and Simulation
  • Computational Theory and Mathematics

Cite this

Pharmacodynamic modeling of anti-cancer activity of tetraiodothyroacetic acid in a perfused cell culture system. / Lin, Hung Yun; Landersdorfer, Cornelia B.; London, David; Meng, Ran; Lim, Chang Uk; Lin, Cassie; Lin, Sharon; Tang, Heng Yuan; Brown, David; van Scoy, Brian; Kulawy, Robert; Queimado, Lurdes; Drusano, George L.; Louie, Arnold; Davis, Faith B.; Mousa, Shaker A.; Davis, Paul J.

In: PLoS Computational Biology, Vol. 7, No. 2, e1001073, 02.2011.

Research output: Contribution to journalArticle

Lin, HY, Landersdorfer, CB, London, D, Meng, R, Lim, CU, Lin, C, Lin, S, Tang, HY, Brown, D, van Scoy, B, Kulawy, R, Queimado, L, Drusano, GL, Louie, A, Davis, FB, Mousa, SA & Davis, PJ 2011, 'Pharmacodynamic modeling of anti-cancer activity of tetraiodothyroacetic acid in a perfused cell culture system', PLoS Computational Biology, vol. 7, no. 2, e1001073. https://doi.org/10.1371/journal.pcbi.1001073
Lin, Hung Yun ; Landersdorfer, Cornelia B. ; London, David ; Meng, Ran ; Lim, Chang Uk ; Lin, Cassie ; Lin, Sharon ; Tang, Heng Yuan ; Brown, David ; van Scoy, Brian ; Kulawy, Robert ; Queimado, Lurdes ; Drusano, George L. ; Louie, Arnold ; Davis, Faith B. ; Mousa, Shaker A. ; Davis, Paul J. / Pharmacodynamic modeling of anti-cancer activity of tetraiodothyroacetic acid in a perfused cell culture system. In: PLoS Computational Biology. 2011 ; Vol. 7, No. 2.
@article{57908046ca2c4613845b192ae6c74727,
title = "Pharmacodynamic modeling of anti-cancer activity of tetraiodothyroacetic acid in a perfused cell culture system",
abstract = "Unmodified or as a poly[lactide-co-glycolide] nanoparticle, tetraiodothyroacetic acid (tetrac) acts at the integrin αvβ3 receptor on human cancer cells to inhibit tumor cell proliferation and xenograft growth. To study in vitro the pharmacodynamics of tetrac formulations in the absence of and in conjunction with other chemotherapeutic agents, we developed a perfusion bellows cell culture system. Cells were grown on polymer flakes and exposed to various concentrations of tetrac, nano-tetrac, resveratrol, cetuximab, or a combination for up to 18 days. Cells were harvested and counted every one or two days. Both NONMEM VI and the exact Monte Carlo parametric expectation maximization algorithm in S-ADAPT were utilized for mathematical modeling. Unmodified tetrac inhibited the proliferation of cancer cells and did so with differing potency in different cell lines. The developed mechanism-based model included two effects of tetrac on different parts of the cell cycle which could be distinguished. For human breast cancer cells, modeling suggested a higher sensitivity (lower IC50) to the effect on success rate of replication than the effect on rate of growth, whereas the capacity (Imax) was larger for the effect on growth rate. Nanoparticulate tetrac (nano-tetrac), which does not enter into cells, had a higher potency and a larger anti-proliferative effect than unmodified tetrac. Fluorescence-activated cell sorting analysis of harvested cells revealed tetrac and nano-tetrac induced concentration-dependent apoptosis that was correlated with expression of pro-apoptotic proteins, such as p53, p21, PIG3 and BAD for nano-tetrac, while unmodified tetrac showed a different profile. Approximately additive anti-proliferative effects were found for the combinations of tetrac and resveratrol, tetrac and cetuximab (Erbitux), and nano-tetrac and cetuximab. Our in vitro perfusion cancer cell system together with mathematical modeling successfully described the anti-proliferative effects over time of tetrac and nano-tetrac and may be useful for dose-finding and studying the pharmacodynamics of other chemotherapeutic agents or their combinations.",
author = "Lin, {Hung Yun} and Landersdorfer, {Cornelia B.} and David London and Ran Meng and Lim, {Chang Uk} and Cassie Lin and Sharon Lin and Tang, {Heng Yuan} and David Brown and {van Scoy}, Brian and Robert Kulawy and Lurdes Queimado and Drusano, {George L.} and Arnold Louie and Davis, {Faith B.} and Mousa, {Shaker A.} and Davis, {Paul J.}",
year = "2011",
month = "2",
doi = "10.1371/journal.pcbi.1001073",
language = "English",
volume = "7",
journal = "PLoS Computational Biology",
issn = "1553-734X",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - Pharmacodynamic modeling of anti-cancer activity of tetraiodothyroacetic acid in a perfused cell culture system

AU - Lin, Hung Yun

AU - Landersdorfer, Cornelia B.

AU - London, David

AU - Meng, Ran

AU - Lim, Chang Uk

AU - Lin, Cassie

AU - Lin, Sharon

AU - Tang, Heng Yuan

AU - Brown, David

AU - van Scoy, Brian

AU - Kulawy, Robert

AU - Queimado, Lurdes

AU - Drusano, George L.

AU - Louie, Arnold

AU - Davis, Faith B.

AU - Mousa, Shaker A.

AU - Davis, Paul J.

PY - 2011/2

Y1 - 2011/2

N2 - Unmodified or as a poly[lactide-co-glycolide] nanoparticle, tetraiodothyroacetic acid (tetrac) acts at the integrin αvβ3 receptor on human cancer cells to inhibit tumor cell proliferation and xenograft growth. To study in vitro the pharmacodynamics of tetrac formulations in the absence of and in conjunction with other chemotherapeutic agents, we developed a perfusion bellows cell culture system. Cells were grown on polymer flakes and exposed to various concentrations of tetrac, nano-tetrac, resveratrol, cetuximab, or a combination for up to 18 days. Cells were harvested and counted every one or two days. Both NONMEM VI and the exact Monte Carlo parametric expectation maximization algorithm in S-ADAPT were utilized for mathematical modeling. Unmodified tetrac inhibited the proliferation of cancer cells and did so with differing potency in different cell lines. The developed mechanism-based model included two effects of tetrac on different parts of the cell cycle which could be distinguished. For human breast cancer cells, modeling suggested a higher sensitivity (lower IC50) to the effect on success rate of replication than the effect on rate of growth, whereas the capacity (Imax) was larger for the effect on growth rate. Nanoparticulate tetrac (nano-tetrac), which does not enter into cells, had a higher potency and a larger anti-proliferative effect than unmodified tetrac. Fluorescence-activated cell sorting analysis of harvested cells revealed tetrac and nano-tetrac induced concentration-dependent apoptosis that was correlated with expression of pro-apoptotic proteins, such as p53, p21, PIG3 and BAD for nano-tetrac, while unmodified tetrac showed a different profile. Approximately additive anti-proliferative effects were found for the combinations of tetrac and resveratrol, tetrac and cetuximab (Erbitux), and nano-tetrac and cetuximab. Our in vitro perfusion cancer cell system together with mathematical modeling successfully described the anti-proliferative effects over time of tetrac and nano-tetrac and may be useful for dose-finding and studying the pharmacodynamics of other chemotherapeutic agents or their combinations.

AB - Unmodified or as a poly[lactide-co-glycolide] nanoparticle, tetraiodothyroacetic acid (tetrac) acts at the integrin αvβ3 receptor on human cancer cells to inhibit tumor cell proliferation and xenograft growth. To study in vitro the pharmacodynamics of tetrac formulations in the absence of and in conjunction with other chemotherapeutic agents, we developed a perfusion bellows cell culture system. Cells were grown on polymer flakes and exposed to various concentrations of tetrac, nano-tetrac, resveratrol, cetuximab, or a combination for up to 18 days. Cells were harvested and counted every one or two days. Both NONMEM VI and the exact Monte Carlo parametric expectation maximization algorithm in S-ADAPT were utilized for mathematical modeling. Unmodified tetrac inhibited the proliferation of cancer cells and did so with differing potency in different cell lines. The developed mechanism-based model included two effects of tetrac on different parts of the cell cycle which could be distinguished. For human breast cancer cells, modeling suggested a higher sensitivity (lower IC50) to the effect on success rate of replication than the effect on rate of growth, whereas the capacity (Imax) was larger for the effect on growth rate. Nanoparticulate tetrac (nano-tetrac), which does not enter into cells, had a higher potency and a larger anti-proliferative effect than unmodified tetrac. Fluorescence-activated cell sorting analysis of harvested cells revealed tetrac and nano-tetrac induced concentration-dependent apoptosis that was correlated with expression of pro-apoptotic proteins, such as p53, p21, PIG3 and BAD for nano-tetrac, while unmodified tetrac showed a different profile. Approximately additive anti-proliferative effects were found for the combinations of tetrac and resveratrol, tetrac and cetuximab (Erbitux), and nano-tetrac and cetuximab. Our in vitro perfusion cancer cell system together with mathematical modeling successfully described the anti-proliferative effects over time of tetrac and nano-tetrac and may be useful for dose-finding and studying the pharmacodynamics of other chemotherapeutic agents or their combinations.

UR - http://www.scopus.com/inward/record.url?scp=79952465499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952465499&partnerID=8YFLogxK

U2 - 10.1371/journal.pcbi.1001073

DO - 10.1371/journal.pcbi.1001073

M3 - Article

C2 - 21304935

AN - SCOPUS:79952465499

VL - 7

JO - PLoS Computational Biology

JF - PLoS Computational Biology

SN - 1553-734X

IS - 2

M1 - e1001073

ER -